Development of an IL-6 Inhibitor Based on the Functional Analysis of Murine IL-6Rα1

Citations of this article
Mendeley users who have this article in their library.


Dysregulated cytokine production contributes to inflammatory and proliferative diseases. Therefore, inhibition of proinflammatory mediators such as TNF, IL-1, and IL-6 is of great clinical relevance. Actual strategies are aimed at preventing receptor activation through sequestration of the ligand. Here we describe the development of an inhibitor of murine IL-6 based on fused receptor fragments. Molecular modeling-guided analysis of the murine IL-6Rα revealed that mutations in the Ig-like domain D1 severely affect protein function, although D1 is not directly involved in the ligand-binding interface. The resulting single chain IL-6 inhibitor (mIL-6-RFP) consisting of domains D1-D3 of mgp130, a flexible linker, and domains D1-D3 of mIL-6Rα is a highly potent and specific IL-6 inhibitor. mIL-6-RFP will permit further characterization of the role of IL-6 in various disease models and could ultimately lead to anti-IL-6 therapy. © 2009 Elsevier Ltd. All rights reserved.

Author supplied keywords




Wiesinger, M. Y., Haan, S., Wüller, S., Kauffmann, M. E., Recker, T., Küster, A., … Müller-Newen, G. (2009). Development of an IL-6 Inhibitor Based on the Functional Analysis of Murine IL-6Rα1. Chemistry and Biology, 16(7), 783–794.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free